Mounjaro, Wegovy sales in India double on month in July
Hyderabad: Sales of weight-loss drugs Wegovy by Danish pharmaceutical giant Novo Nordisk and Mounjaro by U.S.-based Eli Lilly doubled in India in July from a month earlier, according to data from research firm Pharmarack.
The surge reflects rapidly growing demand for these blockbuster anti-obesity treatments in the world’s most populous country,.
Wegovy, which was launched locally in June, saw its sales more than double to 5,000 units or 70 million rupees ($798,230) in July, the data showed.
Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees, Reuters reported.
“Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,” Pharmarack’s Vice President (Commercial) Sheetal Sapale said in a statement.
In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes.
Mounjaro’s sales have soared 15 times since March, when the drug was launched in India.
Facebook Comments
